GSK 2330811

Drug Profile

GSK 2330811

Alternative Names: GSK2330811

Latest Information Update: 17 Jul 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Anti-inflammatories; Antifibrotics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Oncostatin M inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Systemic scleroderma

Most Recent Events

  • 05 Jun 2017 Phase-II clinical trials in Systemic scleroderma in United Kingdom (SC) (NCT03041025)
  • 11 Nov 2016 Safety and pharmacokinetics data from a phase I trial in Systemic scleroderma (In healthy volunteers) presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2016)
  • 27 Jul 2016 GlaxoSmithKline plans a phase II trial in Systemic scleroderma (NCT03041025)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top